Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-24
2011-10-25
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252180, C514S252190, C514S252200, C544S295000
Reexamination Certificate
active
08044055
ABSTRACT:
The invention relates to 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12receptor antagonists in the treatment and/or prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. Formula (I).
REFERENCES:
patent: 6855715 (2005-02-01), Liebeschuetz et al.
patent: 53073586 (1978-06-01), None
patent: WO 02/098856 (2002-12-01), None
patent: WO 2004/052366 (2004-06-01), None
patent: WO 2006/114774 (2006-11-01), None
patent: WO 2008/044217 (2008-04-01), None
patent: WO 2009/069100 (2009-06-01), None
patent: WO 2009/125365 (2009-10-01), None
patent: WO 2009/125366 (2009-10-01), None
patent: WO 2010/116328 (2010-10-01), None
patent: WO 2010/122504 (2010-10-01), None
Feokistov et al., Adenosine A2B receptors, Pharmacological Reviews, vol. 49, No. 4, pp. 381-402, 1997.
Parlow J.J. et al. Bioorg Med Chem Lett. Aug. 15, 2009; 19, 6148-6156. Epub Sep. 10, 2009.
Gould. P. et al., “Salt Selection for Basic Drugs”, Int. J. Pharm. (1986) 33, 201-217.
Parlow J.J. et al., “Piperazinyl-Glutamate-Pyridines as Potent Orally Bioavailable P2Y12 Antagonists for Inhibition of Platelet Aggregation.” Bioorg. Med. Chem. Lett. (2009). doi: 10.1016/j.bmcl.2009.06.075.
Bishop et al., 3-(αR)-α((2S,5R)-4 Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-alkyl-N-arylbenzamides, J. Med. Chem. (2003) 46, 623-633.
Sheth et al., The Influence of Azone, Propylene Glycol and Polyethylene Glycol on in vitro Skin Penetration of Trifluorothymidine, Int. J. Pharm. (1986) 28, 201-209.
Amir, J., et al., “Treatment of thrombotic thrombocytopenic purpura with antiplatelet drugs”,Blood, vol. 42, No. 1, pp. 27-33, (1973).
Antithrombotic Trialists' Collaboration., “Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients”,British Medical Journal, vol. 324, pp. 71-86, (2002).
Balduini, C.L., et al., “Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders”,Coagulation and Transfusion Medicine, vol. 95, No. 1, pp. 82-86, (1991).
Bertrand, M.E., et al., “Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned elective coronary stenting: The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study”,Circulation, vol. 1998, pp. 1597-1603, (1998).
Brighton, T.A., et al., “Antiphospholipid antibodies and thrombosis”,Bailliere's Clinical Haematology, vol. 7, No. 3, pp. 541-557, (1994).
Caprie Steering Committee, “A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)”,The Lancet, vol. 348, pp. 1329-1339, (1996).
Collins, C.E., et al., “Review article: platelets in inflammatory bowel disease—pathogenetic role and therapeutic implications”,Aliment Pharmacol Ther., vol. 11, pp. 237-247, (1997).
Davies, M.J., et al., “Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death”,Circulation, vol. 73, No. 3, pp. 418-427, (1986).
Felfernig-Boehm, D., et al., “Early detection of preeclampsia by determination of platelet aggregability”,Thrombosis Research, vol. 98, pp. 139-146, (2000).
Fox, K.A.A., et al., “Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial”,Circulation, vol. 110, pp. 1202-1208, (2004).
Halushka, P.V., et al., “Protective effects of aspirin in endotoxic shock”,The Journal of Pharmacology and Experimental Therapeutics, vol. 218, pp. 464-469, (1981).
Hovens, M.M.C., et al., “Aspirin in the prevention and treatment of venous thromboembolism”,Journal of Thrombosis and Haemostasis, vol. 4, pp. 1470-1475, (2006).
Kharbanda, R.K., et al., “Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin”,Circulation, vol. 105, pp. 2600-2604, (2002).
Megalopoulos, A., et al., “Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome”,International Angiology, vol. 25, No. 1, pp. 84-89, (2006).
Mehta, S.R., et al., “Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study”,The Lancet, vol. 358, pp. 527-533, (2001).
Payne, D.A., et al., “Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy”,Circulation, vol. 109, pp. 1476-1481, (2004).
Stathakis, N. E., et al., “Platelet dysfunction in essential thrombocythaemia”,Annals of Clinical Research, vol. 6, pp. 198-202, (1974).
Thorsen, C.A., et al., “The treatment of the hemolytic-uremic syndrome with inhibitors of platelet function”,The American Journal of Medicine, vol. 66, pp. 711-716, (1979).
Triadou, P., et al., “Platelet function in sickle cell disease during steady state”,Nouvelle Revue Francaise Hematologie, vol. 32, pp. 137-142, (1990).
University of Perugia, “Aspirin for the prevention of recurrent venous thromboembolism and cardiovascular events”, Sep. 13, 2005, www.clinicaltrials.gov/ct/show/NCT00222677.
Yao, S.K., et al., “Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis”,Am. J. Physiol., vol. 267, pp. H488-H493, (1994).
Caroff Eva
Hilpert Kurt
Meyer Emmanuel
Actelion Pharmaceuticals Ltd.
Hoxie & Associates LLC
Rao Deepak
LandOfFree
2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4280622